SEQUENCE LISTING

<110>  Lundbeck A/S
 
<120>  Antibodies specific for pyroglutamated Abeta

<130>  0805

<160>  55    

<170>  PatentIn version 3.5

<210>  1
<211>  42
<212>  PRT
<213>  Human

<400>  1

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 
1               5                   10                  15      

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
            20                  25                  30          

Gly Leu Met Val Gly Gly Val Val Ile Ala 
        35                  40          


<210>  2
<211>  10
<212>  PRT
<213>  Human


<220>
<221>  pyroglutamate
<222>  (1)..(1)
<223>  the first amino acid "Glu" in the sequence is pyro-glutamated

<220>
<221>  pyroglutamate
<222>  (1)..(1)
<223>  E in position 1 is is pyroglutamated

<400>  2

Glu Phe Arg His Asp Ser Gly Tyr Glu Cys 
1               5                   10  

<210>  3
<211>  10
<212>  PRT
<213>  murine


<220>
<221>  pyroglutamate
<222>  (1)..(1)
<223>  the first amino acid "Glu" in the sequence is pyro-glutamated

<220>
<221>  pyroglutamate
<222>  (1)..(1)
<223>  E in position 1 is is pyroglutamated

<400>  3

Glu Phe Gly His Asp Ser Gly Phe Glu Cys 
1               5                   10  


<210>  4
<211>  345
<212>  DNA
<213>  Artificial

<220>
<223>  antibody variable region

<400>  4
cagatccagc tgcagcagtc tggacctgag ctggtgaagc ctggggctgc agtgaagata     60

tcctgcaagg cttctggcta caccttcact gactactatt taaactgggt gaagcaaaag    120

cctggacagg gacttgagtg gattggatgg atttatcctg gaagcggtaa tgttaaatat    180

aatgagaagt tcaagggcaa ggccacattg actgcagaca cttcctccaa ca-cagcccac    240

atgcagctca gcagcctgac atctgaggac actgctgtct atttctgtac aa-gagagggg    300

ctcattgttt attggggcca agggactctg gtcactgtct ctgca                    345

<210>  5
<211>  115
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  5

Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      

Ala Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          

Tyr Leu Asn Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              

Gly Trp Ile Tyr Pro Gly Ser Gly Asn Val Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  

Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala His 
65                  70                  75                  80  

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      

Thr Arg Glu Gly Leu Ile Val Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         

Val Ser Ala 
        115 


<210>  6
<211>  336
<212>  DNA
<213>  artificial

<220>
<223>  antibody variable region

<400>  6
gatgttgtgc tgacccagac tccattcact ttgtcggtta ccattggaca ac-cagcctct     60

atctcttgca agtcaagtca gagcctctta catagtaatg gagaaagcta tttgaattgg    120

ttatttcaga ggccaggcca gtctccaaag cgcctaatct atgcggtgtc taaactggac    180

tctggagtcc ctgacaggtt cactggcagt ggatcaggaa cagattttac actgaaaatc    240

agcagagtgg aggctgagga tttgggagtt tattactgcg tgcaaggtac acattttccg    300

ttcacgttcg gaggggggac caagctggaa ataaaa                              336


<210>  7
<211>  112
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  7

Asp Val Val Leu Thr Gln Thr Pro Phe Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          

Asn Gly Glu Ser Tyr Leu Asn Trp Leu Phe Gln Arg Pro Gly Gln Ser 
        35                  40                  45              

Pro Lys Arg Leu Ile Tyr Ala Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Val Gln Gly 
                85                  90                  95      

Thr His Phe Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         

<210>  8
<211>  345
<212>  DNA
<213>  artificial

<220>
<223>  antibody variable region

<400>  8
cagatccagc tgcagcagtc tggacctgac ctggtgaagc ctggggcttc agtgaagata     60

tcctgcaagg cttctggcta caccttcact gactactata taaactgggt caagcagaag    120

cctggacagg gacttgagtg gattggatgg cttaatcctg gaagcggtaa tac-taagtac    180

aatgagaagt tcaagggcaa ggccacaatg actgtggaca caacctccag ta-cagtttac    240

atgcagctca gcagcctgac atctgaggac tctgctgtct atttctgtac aa-gagaagga    300

cctatcgact actggggtcg aggaacctca gtcaccgtct cctca                    345


<210>  9
<211>  115
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  9

Gln Ile Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Ile Asn Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Leu Asn Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Met Thr Val Asp Thr Thr Ser Ser Thr Val Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Glu Gly Pro Ile Asp Tyr Trp Gly Arg Gly Thr Ser Val Thr 
            100                 105                 110         

Val Ser Ser 
        115 
 
<210>  10
<211>  336
<212>  DNA
<213>  artificial

<220>
<223>  antibody variable region

<400>  10
gatgttgtgc tgacccagac tccactcact ttgtcggtta ccattggaca acccgcctct     60

atctcttgca agtcaagtca gagcctctta tatagtaatg gaaaaaccta tttgaattgg    120

ttattacaga ggccaggtca gtctccgaag cgcctaatct atgtggtgtc taaactggac    180

tctggagtcc ctgacaggtt cactggcagt ggatcaggaa cagatttcac actgaaaatc    240

agcagagtgg aggctgagga tttgggagtt tattactgcg tgcaaggtac acattatccg    300

ttcacgttcg gaggggggac caagctggaa ataaaa                              336


<210>  11
<211>  112
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  11

Asp Val Val Leu Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          

Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              

Pro Lys Arg Leu Ile Tyr Val Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Val Gln Gly 
                85                  90                  95      

Thr His Tyr Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         

<210>  12
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  12

Gly Tyr Thr Phe Thr Asp Tyr Tyr Leu Asn 
1               5                   10  


<210>  13
<211>  17
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  13

Trp Ile Tyr Pro Gly Ser Gly Asn Val Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      

Gly 
    


<210>  14
<211>  6
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  14

Glu Gly Leu Ile Val Tyr 
1               5       

<210>  15
<211>  16
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  15

Lys Ser Ser Gln Ser Leu Leu His Ser Asn Gly Glu Ser Tyr Leu Asn 
1               5                   10                  15      


<210>  16
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  16

Ala Val Ser Lys Leu Asp Ser 
1               5           


<210>  17
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  17

Val Gln Gly Thr His Phe Pro Phe Thr 
1               5                   


<210>  18
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  18

Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Asn 
1               5                   10  


<210>  19
<211>  17
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  19

Trp Leu Asn Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      

Gly 
    


<210>  20
<211>  6
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  20

Glu Gly Pro Ile Asp Tyr 
1               5       


<210>  21
<211>  16
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  21

Lys Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Lys Thr Tyr Leu Asn 
1               5                   10                  15      

<210>  22
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  22

Val Val Ser Lys Leu Asp Ser 
1               5           


<210>  23
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  23


Val Gln Gly Thr His Tyr Pro Phe Thr 
1               5                   


<210>  24
<211>  342
<212>  DNA
<213>  artificial

<220>
<223>  antibody variable region

<400>  24
gaagtgaagc ttgaggagtc tggaggaggc ttggtgcaac ctggaggatc cat-gaaactc     60

tcgtgtactg cctctggact cactcttagt gacgcctgga tgaactgggt ccgccagtct    120

ccagagaagg ggcttgagtg ggttgctgaa attagaagca aagcttataa gcatgcaaca    180

tactatgctg agtctgtgaa aggcaggttc accatctcaa gagatgattc caaaagttgt    240

atctacctgc aaatgaacac cttaagagct gaggacactg gcatttatta ctgtaccaga    300

catggttctt ggggcccagg gactctggtc actgtctctg ca                       342

<210>  25
<211>  114
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  25

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      

Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Leu Thr Leu Ser Asp Ala 
            20                  25                  30          

Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              

Ala Glu Ile Arg Ser Lys Ala Tyr Lys His Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Cys 
65                  70                  75                  80  

Ile Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Gly Ile Tyr 
                85                  90                  95      

Tyr Cys Thr Arg His Gly Ser Trp Gly Pro Gly Thr Leu Val Thr Val 
            100                 105                 110         

Ser Ala 
      

<210>  26
<211>  321
<212>  DNA
<213>  artificial

<220>
<223>  antibody variable region

<400>  26
gacatcctga tgtcccaatc tccatcctcc atgtctgttt ctctgggaga ca-gagtcagc     60

atcacttgcc gtgcaagtca gggaattagt agtaaaatgg ggtggttgca gca-gaaacca    120

gggaaatcat ctaagggcct gatctatcat ggaaccaagt tggaagatgg agttccatcg    180

aggttcagtg gcagtggatc tggagcagaa tattctctca ccatcagtag cctggaatct    240

gaggattttg gagactatta ctgtgtacag tatgctcagt ttccgtacac gttcggaggg    300

gggaccaagc tggaaataaa a                                              321


<210>  27
<211>  107
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  27

Asp Ile Leu Met Ser Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly 
1               5                   10                  15      

Asp Arg Val Ser Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Lys 
            20                  25                  30          


Met Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Ser Lys Gly Leu Ile 
        35                  40                  45              

Tyr His Gly Thr Lys Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  

Ser Gly Ser Gly Ala Glu Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 
65                  70                  75                  80  

Glu Asp Phe Gly Asp Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Tyr 
                85                  90                  95      

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  28
<211>  346
<212>  DNA
<213>  artificial

<220>
<223>  antibody variable region

<400>  28
gagtgaagtg aaacttgagg agtctggagg aggcttggta caacctggag gatccatgaa     60

actctcttgt actgcctctg gaatcactct taatgacgcc tggatgacct gggtccgcca    120

gtctccagag aaggggcttg agtgggttgg tgaaattaga aacaaagcta ataatcatgc    180

aacaaactat gctgagtctg tgaaagggag gttcagcatc tcaagagatg attccaaagg    240

tattgtctac ctgcaaatga atagcttaag agctgaagac actggcaatt at-tactgtac    300

caggcattct tactggggcc cagggactct ggtcactgtc tctgca                   346


<210>  29
<211>  114
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  29

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      

Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Ile Thr Leu Asn Asp Ala 
            20                  25                  30          

Trp Met Thr Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              

Gly Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asn Tyr Ala Glu 
    50                  55                  60                  

Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Gly Ile 
65                  70                  75                  80  

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Asn Tyr 
                85                  90                  95      

Tyr Cys Thr Arg His Ser Tyr Trp Gly Pro Gly Thr Leu Val Thr Val 
            100                 105                 110         

Ser Ala 
        


<210>  30
<211>  321
<212>  DNA
<213>  artificial

<220>
<223>  antibody variable region

<400>  30
gacatcctga tgacccaatc tccatcctcc atgtctgtat ctctgggaga ca-cagtcagc     60

atcacgtgcc atgcaagtca gggcattaga aataatatag ggtggttgca gga-gaaacca    120

gggaaatcat ttaagggcct gatctatcat ggaaccaagt tggaagatgg aattccatca    180

aggttcagtg gcagtggatc tggagcagat tattctctca ccatcagtag cctggaatct    240

gaagatgttg cagactatta ctgtgtacaa tatgatcagt ttccgtacac gttcggaggg    300

gggaccaagc tggaaataaa a                                              321


<210>  31
<211>  107
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  31

Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly 
1               5                   10                  15      

Asp Thr Val Ser Ile Thr Cys His Ala Ser Gln Gly Ile Arg Asn Asn 
            20                  25                  30          

Ile Gly Trp Leu Gln Glu Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 
        35                  40                  45              

Tyr His Gly Thr Lys Leu Glu Asp Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  

Ser Gly Ser Gly Ala Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 
65                  70                  75                  80  

Glu Asp Val Ala Asp Tyr Tyr Cys Val Gln Tyr Asp Gln Phe Pro Tyr 
                85                  90                  95      

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


 
<210>  32
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  32

Gly Leu Thr Leu Ser Asp Ala Trp Met Asn 
1               5                   10  


<210>  33
<211>  19
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  33

Glu Ile Arg Ser Lys Ala Tyr Lys His Ala Thr Tyr Tyr Ala Glu Ser 
1               5                   10                  15      

Val Lys Gly 
            


<210>  34
<211>  3
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  34

His Gly Ser 
1           


<210>  35
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  35

Arg Ala Ser Gln Gly Ile Ser Ser Lys Met Gly 
1               5                   10      


<210>  36
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  36

His Gly Thr Lys Leu Glu Asp 
1               5           


<210>  37
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  37

Val Gln Tyr Ala Gln Phe Pro Tyr Thr 
1               5                   


<210>  38
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  38

Gly Ile Thr Leu Asn Asp Ala Trp Met Thr 
1               5                   10  

<210>  39
<211>  19
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  39

Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asn Tyr Ala Glu Ser 
1               5                   10                  15      

Val Lys Gly 
            


<210>  40
<211>  3
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  40

His Ser Tyr 
1           


<210>  41
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  41


His Ala Ser Gln Gly Ile Arg Asn Asn Ile Gly 
1               5                   10      

<210>  42
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  42

His Gly Thr Lys Leu Glu Asp 
1               5           


<210>  43
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  Complementarity determining region

<400>  43

Val Gln Tyr Asp Gln Phe Pro Tyr Thr 
1               5                   


<210>  44
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (9)..(9)
<223>  X in position 9 can be I or L

<400>  44


Gly Tyr Thr Phe Thr Asp Tyr Tyr Xaa Asn 
1               5                   10  


<210>  45
<211>  17
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (2)..(2)
<223>  X in position 2 may be I or L

<220>
<221>  X
<222>  (3)..(3)
<223>  X in position 3 Y or N

<220>
<221>  X
<222>  (9)..(9)
<223>  X in position 9  V or T

<400>  45

Trp Xaa Xaa Pro Gly Ser Gly Asn Xaa Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      

Gly 
    


<210>  46
<211>  6
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (3)..(3)
<223>  X in position 3 may be I or L

<220>
<221>  X
<222>  (4)..(4)
<223>  X in position 4 may be I or P

<220>
<221>  X
<222>  (5)..(5)
<223>  X in position 5 may be V or D

<400>  46

Glu Gly Xaa Xaa Xaa Tyr 
1               5       


<210>  47
<211>  16
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (8)..(8)
<223>  X in position 8 may be H or Y

<220>
<221>  X
<222>  (12)..(12)
<223>  X in position 12 may be E or K

<220>
<221>  X
<222>  (13)..(13)
<223>  X in position 13 may be T or S

<400>  47


Lys Ser Ser Gln Ser Leu Leu Xaa Ser Asn Gly Xaa Xaa Tyr Leu Asn 
1               5                   10                  15      

<210>  48
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (1)..(1)
<223>  X in position 1 may be A or V

<400>  48

Xaa Val Ser Lys Leu Asp Ser 
1               5           


<210>  49
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (6)..(6)
<223>  X in position 6 may be Y or F

<400>  49

Val Gln Gly Thr His Xaa Pro Phe Thr 
1               5                   


<210>  50
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (2)..(2)
<223>  X in position 2 may be I or L

<220>
<221>  X
<222>  (5)..(5)
<223>  X in position 5 may be S or N

<220>
<221>  X
<222>  (10)..(10)
<223>  X in position 10 may be N or T

<400>  50

Gly Xaa Thr Leu Xaa Asp Ala Trp Met Xaa 
1               5                   10  


<210>  51
<211>  19
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (4)..(4)
<223>  X in position 4 may be S or N

<220>
<221>  X
<222>  (7)..(7)
<223>  X in position 7 may be Y or N

<220>
<221>  X
<222>  (8)..(8)
<223>  X in position 8 may be K or N

<220>
<221>  X
<222>  (12)..(12)
<223>  X in position 12 Y or N

<400>  51

Glu Ile Arg Xaa Lys Ala Xaa Xaa His Ala Thr Xaa Tyr Ala Glu Ser 
1               5                   10                  15      

Val Lys Gly 
            


<210>  52
<211>  3
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (2)..(2)
<223>  X in position 2 may be G or S

<220>
<221>  X
<222>  (3)..(3)
<223>  X in position 3 may be S or Y

<400>  52

His Xaa Xaa 
1           


<210>  53
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (1)..(1)
<223>  X in position 1 may be R or H

<220>
<221>  X
<222>  (7)..(7)
<223>  X in position 7 may be S or R

<220>
<221>  X
<222>  (8)..(8)
<223>  X in position 8 may be S or N

<220>
<221>  X
<222>  (9)..(9)
<223>  X in position 9 may be K or N

<220>
<221>  X
<222>  (10)..(10)
<223>  X in position 10 may be M or I

<400>  53

Xaa Ala Ser Gln Gly Ile Xaa Xaa Xaa Xaa Gly 
1               5                   10      

<210>  54
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region

<400>  54

His Gly Thr Lys Leu Glu Asp 
1               5           


<210>  55
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  antibody variable region


<220>
<221>  X
<222>  (4)..(4)
<223>  X in position 4 may be A or D

<400>  55

Val Gln Tyr Xaa Gln Phe Pro Tyr Thr 
1               5                   
